KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) FCF Margin (2019 - 2025)

Royalty Pharma (RPRX) has disclosed FCF Margin for 7 consecutive years, with 15.03% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 2643.0% to 15.03% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 33.31% through Dec 2025, up 2168.0% year-over-year, with the annual reading at 33.31% for FY2025, 2168.0% up from the prior year.
  • FCF Margin hit 15.03% in Q4 2025 for Royalty Pharma, up from 42.55% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 104.71% in Q1 2025 to a low of 147.88% in Q3 2021.
  • Historically, FCF Margin has averaged 19.22% across 5 years, with a median of 48.37% in 2021.
  • Biggest five-year swings in FCF Margin: skyrocketed 15840bps in 2023 and later plummeted -11481bps in 2024.
  • Year by year, FCF Margin stood at 55.28% in 2021, then rose by 2bps to 56.51% in 2022, then plummeted by -168bps to 38.52% in 2023, then skyrocketed by 208bps to 41.46% in 2024, then plummeted by -64bps to 15.03% in 2025.
  • Business Quant data shows FCF Margin for RPRX at 15.03% in Q4 2025, 42.55% in Q3 2025, and 62.71% in Q2 2025.